Vaxxas HD-MAP to deliver vaccines directly to the skin
Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.
Biotechnology company, Vaxxas, has received a US$5 million grant from the Bill & Melinda Gates Foundation to conduct first-in-human human clinical studies using the company’s High-Density Microneedle Array Patch (HD-MAP) for measles and rubella vaccination.
The measles and rubella vaccine formulation used to coat the HD-MAP has been engineered to be stable at higher temperatures than required for needle/syringe vaccination. This improved thermal stability can reduce the cost and complexity of the cold distribution chain that is required for many conventional vaccines, enabling distribution of HD-MAP vaccines to parts of the world where refrigeration is unreliable or even nonexistent.
Professor David Durrheim, University of Newcastle and Chair of the Western Pacific Measles and Rubella Regional Verification Commission explained the need for new vaccine delivery methods that overcome the current limitations of needle and syringe vaccine delivery by skilled health professionals with reliable refrigeration is urgent.
The micro-array patches, could, according to Professor Durrheim be regarded as a potential “game-changer”.
The proprietary HD-MAP platform induces robust immune system activation by targeting relevant vaccine components to the abundant immunological cells immediately below the surface of the skin. In Vaxxas’ most recent clinical study evaluating performance using influenza vaccine, the HD-MAP using 1/6 dose induced similar immune response to full dose by needle and syringe.
Through the grant funding of the foundation, Vaxxas will optimize its HD-MAP measles and rubella vaccine in a number of important ways, including ensuring the vaccine is stable for a period at room temperature combined with a product design that will allow the vaccine to be administered by individuals with minimal to no formal medical training as may be necessary in certain countries and regions.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance